Ocuphire Pharma Investor Presentation Deck
A New, Differentiated MOA and Combination Therapy Offers Tunability
Nyxol's potential
differentiation:
1) New MOA class (iris dilator
muscle inhibitor)
2) Favorable safety and
tolerability (e.g.: no
headaches, no
accommodative spasm, no
risk of retinal detachment)
3) 24-hour durability
4) Broad range of patients
including high myopes
5) Improvement in night
vision disturbances
➤ Nyxol+LDP may
offer added efficacy
and tunability
Ocuphire
PHARMA
Other Cholinergic
Agonists*
Alpha
Antagonist
Alpha
Antagonist
& low dose
pilocarpine*
Ocuphire
Nyxol
(0.75% phentolamine)
Visus
BrimocholⓇ
(carbachol + brim)
Ocuphire
Nyxol + 0.4% pilo
Lens
Softening
Corporate Websites as of July 31, 2023,
Grzybowski, A, Markeviciute A, Zemaitiene R. A Review of Pharmacological Presbyopia Treatment. 2020
X
Novartis
EV-006
Lenz
Aceclidine;
Aceclidine + brim
NDA
Allergan
VUITYTM;
(1.25% pilo)
Orasis
CSF-1 (Low dose pilo)
Phase 3
Phase 2
Eyenovia
MicroLine (2% pilo)
Phase 1
*
Pupil modulation
MOA
Combination
drugs
Lens softening
MOA
acts on sphincter and
ciliary muscles in dose-
dependent manner
Cholinergic
Agonist* (pilocarpine)
39View entire presentation